MAIA Biotechnology, Inc.

2:30 PM - 2:45 PM, Monday, June 3, 2019 ・ Theater 4
MAIA Biotechnology, Inc. is positioned to translate cutting-edge science into promising first-in-class drugs into the clinic. We are developing targeted cancer therapies within a diversified and broad portfolio of drug candidates which have shown target engagement and preclinical activity in multiple tumor types. The current pipeline comprises five compounds with distinctively different mode-of-action, targeting lung cancer, CRC, pancreatic, head and neck, prostate and breast cancer, melanoma and brain tumors. A privately-held company based in Chicago and Houston, MAIA was strategically developed to address and leverage the untapped potential of academic labs and scientific inventors. MAIA has a meaningful combination of a principled and dynamic Management Team with in-depth drug development experience, extensive connections to academic institutions, access to seasoned pharma executives and key opinion leaders, and importantly, connections to an extensive network of investors.
Not Provided.
Not Provided.
Company Type:
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):